Join Our Exclusive Family Office Investor Event to learn more about Arterez.
Cardiovascular Disease (CVD) is the world’s leading chronic killer impacting more than one-third of the world’s population. US direct and indirect healthcare costs due to CVD is expected to grow to an estimated $1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the largest health risk and cost.
Dr. J.B. Tunac and Arterez believe they have discovered the multi-factorial root causes of chronic vascular disease and that those can be identified, characterized, cured and ultimately prevented. The company’s first drug, Embotricin™, targets healing at the cellular level rather than targeting symptoms. The company has also developed a biomarker panel for treatment monitoring, known as GlycoCardia™ that can also be used for disease identification, staging and classification. Embotricin™ proved to prevent and reverse arterial plaques in models and proved non-toxic up to 300x the effective dose. First in-human studies are expected to begin Q1 2023.
